Delcath Systems, Inc.
(DCTH)
Add Watchlist
7.57 USD +0.09
Closed: 17 May, 3:55 pm
Symbol DCTH
Market Cap 210.3M
Price 7.57
Open 7.05
52-wk High 7.99
50 Day Avg 5.00
Earnings Announcement 2024-08-07
Website https://www.delcath.com
Name Delcath Systems, Inc.
Shares Outstanding 27,785,800
Change % 8.7644%
Low 7.00
52-wk Low 2.25
200 Day Avg 4.20
Last Dividend 0.00
Exchange NASDAQ
Volume 332,079
Previous Close 6.96
High 7.71
EPS -2.94
PE -2.57
Avg Volume 251,527
CUSIP 24661P807
Delcath Systems, Inc. Outlook
Description Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Currency USD
ISIN US24661P8077
Industry Healthcare
Changes 0.61
CUSIP 24661P807
Range 2.25 - 7.99
Beta 0.55
CIK 0000872912

Delcath Systems, Inc. News

17-May-2024 10:56 AM

Wall Street Analysts Predict a 201.72% Upside in Delcath Systems (DCTH): Here's What You Should Know

The mean of analysts' price targets for Delcath Systems (DCTH) points to a 201.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

15-May-2024 9:50 AM

What Makes Delcath Systems (DCTH) a Good Fit for 'Trend Investing'

Delcath Systems (DCTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

14-May-2024 2:16 PM

Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript

Delcath Systems Inc (NASDAQ:DCTH ) Q1 2024 Results Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary and Chief Compliance Officer Gerard Michel - Chief Executive Officer Sandra Pennell - Senior Vice President of Finance Kevin Muir - General Manager, Interventional Oncology Conference Call Participants William Maughan - Canaccord Genuity LLC Marie Thibault - BTIG Yale Jen - Laidlaw & Company Sean Lee - H.C. Wainwright & Co., LLC Operator Good day.

14-May-2024 7:30 AM

Delcath Systems Reports First Quarter 2024 Results and Business Highlights

Conference Call Today at 8:30 am Eastern Time QUEENSBURY, N.Y. , May 14, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the first quarter ended March 31, 2024.

07-May-2024 8:30 AM

Delcath Systems to Host First Quarter 2024 Earnings Call

QUEENSBURY, N.Y. , May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 14, 2024, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2024.

06-May-2024 9:00 AM

Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%) Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate NEW YORK , May 6, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of results from the pivotal Phase 3 FOCUS study of HEPZATO KIT (melphalan/Hepatic Delivery System) in patients with unresectable metastatic Uveal Melanoma (mUM) on May 5, 2024 in the  journal Annals of Surgical Oncology.

03-May-2024 5:15 PM

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK , May 3, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of two individuals whose employment commenced in April 2024.   The grants totaled the right to purchase an aggregate of 33,000 shares of the Company's common stock and is subject to the terms and conditions of the Company's 2023 Inducement Plan ("Plan").

23-Apr-2024 10:56 AM

How Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83%

The mean of analysts' price targets for Delcath Systems (DCTH) points to a 244.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

05-Apr-2024 10:56 AM

Can Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 277.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

04-Apr-2024 8:35 AM

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK , April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of one individual whose employment commenced in March 2024. The grant totaled the right to purchase an aggregate of 30,000 shares of the Company's common stock and is subject to the terms and conditions of the Company's 2023 Inducement Plan ("Plan").

02-Apr-2024 1:01 PM

Delcath Systems (DCTH) Upgraded to Buy: What Does It Mean for the Stock?

Delcath Systems (DCTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).